Acepodia Announced CEO Dr. Sonny Hsiao’s Appointment as Chairman and Extraordinary Shareholders’ Meeting Agenda

Acepodia (The Company, 6976:TT), a clinical-stage biotechnology company pioneering allogeneic cell therapies, announced today that its current CEO, Dr. Sonny Hsiao, has been unanimously appointed by the Board of Directors to succeed Dr. Patrick Yang as Chairman of the Board, effective January 2025. Dr. Yang, Acepodia’s Co-Founder and current Chairman, will retire at the end of 2024 and transition to the role of Co-Founder and Advisor to support a smooth leadership transition and Acepodia’s long-term growth.

Over the past seven years, Dr. Pat Yang has successfully guided Acepodia’s transformation from a startup to a clinical-stage leader in allogeneic cell therapies. Reflecting on his tenure, Dr. Yang remarked, “Acepodia has reached a pivotal milestone in its journey. I have complete confidence in Dr. Sonny Hsiao’s leadership and expertise to steer the company toward even greater achievements in the years ahead.”

Dr. Hsiao, who co-founded Acepodia with Dr. Yang in 2017, has served as CEO and led the development of the company’s innovative Antibody-Cell Conjugation (ACC) and allogeneic γδ2 T cell platforms. Under his leadership, Acepodia has achieved breakthroughs in drug conjugate technologies and advanced multiple allogeneic cell therapy programs into clinical trials. Dr. Hsiao stated, “I am deeply honored by the trust placed in me by Dr. Yang and the Board. Together with the management team, I remain committed to driving innovation across R&D, manufacturing, clinical trials, and business development, with the goal of delivering transformative therapies to patients around the globe.”

Additionally, the company announced that an Extraordinary Shareholders' Meeting will be convened to elect an additional board member, nominating Dr. Carolyn Bertozzi, recipient of the 2022 Nobel Prize in Chemistry, as a candidate. Dr. Bertozzi’s groundbreaking work in biochemistry and bioorthogonal chemistry will provide strategic and technical insights to further strengthen Acepodia’s platform and pipeline development.

This management transition marks a new chapter for Acepodia, symbolizing its continued commitment to solidifying its leadership in the field of allogeneic cell therapy and achieving further innovative milestones.